In the BioHarmony Drug Report Database

"Preview" Icon

Lanreotide

Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline Depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.

 

Trade Name

 

Somatuline Depot
 

Common Name

 

lanreotide
 

ChEMBL ID

 

CHEMBL1201185
 

Indication

 

acromegaly, neuroendocrine tumors
 

Drug Class

 

Peptides: inhibition of growth hormone release

Image (chem structure or protein)

Lanreotide structure rendering